Caged ligands and uses thereof

Details Caged ligands and uses thereof Caged ligands and uses thereof

2003-10-22

2011-12-13

Vu, Jake M. (Department: 1618)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C424S198100

Reexamination Certificate

active

08076318

ABSTRACT:
Provided are caged compounds comprising a ligand that specifically reacts with a receptor not naturally present in mammals. The cage is released from the ligand upon illumination of the compound with light. Also provided are cells transfected with a gene of interest and a gene encoding a receptor, the gene of interest operably linked to a genetic element capable of being induced by the receptor when bound to a ligand, and the receptor not naturally present in the species of the cell. The cells also comprise a caged ligand of the receptor. Additionally provided are methods of inducing a gene of interest in the above cells. Also provided are methods of repressing a gene of interest in a cell using caged ligands of receptors. Methods are additionally provided for inducing elimination of a target sequence in a cell of a species, using a caged ligand and a recombinase.

REFERENCES:
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5635608 (1997-06-01), Haugland et al.
patent: 6242188 (2001-06-01), Dattagupta et al.
patent: 6258603 (2001-07-01), Carlson et al.
patent: 6514722 (2003-02-01), Palsson et al.
patent: 6803479 (2004-10-01), Kao et al.
patent: 2002/0152493 (2002-10-01), Allen
patent: 2004/0023203 (2004-02-01), Miesenbock et al.
patent: 2004/0166553 (2004-08-01), Nguyen et al.
patent: 2005/0051706 (2005-03-01), Witney et al.
patent: 2005/0054024 (2005-03-01), Lawrence
patent: 2005/0059028 (2005-03-01), Nguyen et al.
patent: 2005/0282203 (2005-12-01), Nguyen et al.
patent: 2006/0211075 (2006-09-01), Lawrence et al.
patent: 2007/0254312 (2007-11-01), Lawrence
patent: 2008/0318246 (2008-12-01), Lawrence et al.
patent: 2009/0035796 (2009-02-01), Lawrence et al.
patent: WO 2004/018686 (2004-03-01), None
patent: WO 2008/070152 (2008-06-01), None
patent: WO 2008/085260 (2008-07-01), None
Lawrence D S et al., entitled “The preparation and in vivo applications of caged peptides and proteins,” Current Opinion in Chemical Biology 2005, 9:570-575.
Chen C A et al., entitled “Design and synthesis of a fluorescent reporter of protein kinase activity,” J Am Chem Soc., Apr. 17, 2002;124(15):3840-1.
Yeh R H et al., “Real Time Visualization of Protein Kinase Activity in Living Cells,” The Journal of Biological Chemistry, 277(13): 11527-11532, 2002.
Sharma V et al., entitled “Peptide-based Fluorescent Sensors of Protein Kinase Activity: Design and Applications,” Biochim Biophys Acta., Jan. 2008; 1784(1):94-99.
Sharma et al., entitled “Deep Quench: An Expanded Dynamic Range for Protein Kinase Sensors,” J Am Chem Soc., Mar. 14, 2007; 129(10):2742-2743.
PCT International Preliminary Examination Report received from the U.S. Patent Trademark Office in connection with PCT International Patent Application No. PCT/US2003/33438, 3 pages.
Adams, S.R. and Tsien, R.Y. (1993) “Controlling Cell Chemistry with Caged Compounds.” Annu. Rev. Physiol. vol. 55. pp. 755-784.
Albanese, C. et al. (2002) “Recent advances in inducible expression in transgenic mice.” Sem. in Cell & Develop. Biol. vol. 13. pp. 129-141.
Albanese, C. et al. (2000) “Sustained mammary gland-directed, ponasterone A-inducible expression in transgenic mice.” FASEB J. vol. 14, pp. 877-884.
Ando, H. et al. (2001) “Photo-mediated gene activation using caged RNA/DNA in zebrafish embryos.” Nature Genetics. vol. 28. pp. 317-325.
Arakawa, H. et al. (2001) “Mutant loxP vectors for selectable marker recycle and conditional knock-outs.” BMC Biotechnol. vol. 1, No. 7. pp. 1472-1479.
Belshaw, P.J. et al. (1996) “Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization.” Chem. Biol. vol. 3, No. 9. pp. 731-738.
Chen, J.D. and Evans, R.M. (1995) “A transcriptional co-repressor that interacts with nuclear hormone receptors.” Nature vol. 377, pp. 454-457.
Cronin, C.A. et al. (2001) “The lac operator-repressor system is functional in the mouse.” Genes Dev. vol. 15. pp. 1506-1517.
Cruz, F.G. et al. (2000) “Light-Activated Gene Expression.” J. Am. Chem. Soc. vol. 122. pp. 8777-8778.
Curley, K. and Lawrence, D.S. (1999) “Light-activated proteins.” Cur. Opin. Chem. Biol. vol. 3. pp. 84-88.
Dinan, L. et al. (1999) “An extensive ecdysteroid CoMFA.” J. Comput. Aided Mol. Des. vol. 13. pp. 185-207.
Feil, R. et al. (1996) “Ligand-activated site-specific recombinaton in mice.” Proc. Natl. Acad. Sci. USA. vol. 93. pp. 10887-10890.
Fisher, G.H. et al. (1999) “Development of a flexible and specific gene delivery system for production of murine tumor models.” Oncogene. vol. 18. pp. 5253-5260.
Furuta, T. et al. (1999) “Brominated 7-hydroxycoumarin-4-ylmethyls: Photolabile protecting groups with biologically useful cross-sections for two photon photolysis.” Proc. Natl. Acad. Sci. USA. vol. 96. pp. 1193-1200.
Gingrich, J.R. and Roder, J. (1998) “Inducible Gene Expression in the Nervous System of Transgenic Mice.” Annu. Rev. Neurosci. vol. 21. pp. 377-405.
Mikitani, K. (1996) “A New Nonsteroidal Chemical Class of Ligand for the Ecdysteroid Receptor 3, 5-di-tert-butyl-4-hydroxy-N-isobutyl-benzamide Shows Apparent Insect Molting Hormone Activities at Molecular and Cellular Levels.” Biochem. Biophys. Res. Comm. vol. 227. pp. 427-432.
Monroe, W.T. et al. (1999) “Targeting Expression with Light Using Caged DNA.” J. Biol. Chem. vol. 274. No. 30. pp. 20895-20900.
Nagy, A. (2000) “Cre Recombinase: The Universal Reagent for Genome Tailoring.” Genesis. vol. 26, pp. 99-109.
No, D. et al. (1996) “Ecdysone-inducible gene expression in mammalian cells and transgenic mice.” Proc Natl Acad Sci USA. vol. 93. pp. 3346-3351.
Orsulic, S. et al. (2002) “Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.” Cancer Cell. vol. 1. pp. 53-62.
Pao, E. et al. (2003) “Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance.” Proc. Natl. Acad. Sci. USA. vol. 100. No. 15. pp. 8764-8769.
Petit, D.L. et al. (1997) “Chemical Two-Photon Uncaging: a Novel Approach to Mapping Glutamate Receptors.” Neuron. vol. 19. pp. 465-471.
Ryding, A.D.S. et al. (2001) “Conditional transgenic technologies.” J. Endocrinol. vol. 171. pp. 1-14.
Saez, E. et al. (2000) “Identification of ligands and coligands for the ecdysone-regulated gene switch.” Proc. Natl. Acad. Sci. USA. vol. 97. No. 26. pp. 14512-14517.
Shockett, P.E. and Schatz, D.G. (1996) “Diverse strategies for tetracycline-regulated inducible gene expression.” Proc. Natl. Acad. Sci. USA. vol. 93. pp. 5173-5176.
Wang, J. et al. (1998) “ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.” Proc. Natl. Acad. Sci. USA. vol. 95. pp. 10860-10865.

Affiliated with

Also associated with

Rating

Caged ligands and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Caged ligands and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Caged ligands and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4254867